Havrix Junior

Havrix Junior is an inactivated hepatitis A virus vaccine formulated with aluminium hydroxide as an adjuvant. It is supplied as a sterile intramuscular injection intended for pediatric use in the European Union. The vaccine contains a standardized amount of inactivated hepatitis A virus particles to stimulate an immune response, and the aluminium hydroxide component enhances antibody production. Havrix Junior is prescription‑only and classified as a preventive viral vaccine.

Havrix Junior is indicated for active immunization against hepatitis A in children and adolescents. It is used as part of routine pediatric vaccination programs to reduce the risk of infection from contaminated food or water.

- Administered as a single intramuscular injection for primary immunization - Can be followed by a booster dose according to national schedules - Suitable for children aged 1 year and older - Provides long‑term protection against hepatitis A virus - Used in travelers to endemic regions after consulting a healthcare professional

The safety profile of Havrix Junior reflects typical responses to inactivated viral vaccines. Common reactions are usually mild and transient, while serious events are rare.

Common: - Mild pain or tenderness at the injection site - Low‑grade fever lasting less than 24 hours - Headache or mild fatigue after vaccination - Redness or swelling around the injection area - Mild rash or itching near the injection area

Serious: - Severe allergic reaction such as anaphylaxis - Persistent high fever exceeding 39°C for more than 48 hours - Neurological symptoms like Guillain‑Barré syndrome - Unexplained bleeding or bruising at the injection site

Before administering Havrix Junior, healthcare providers should review the child's medical history and assess potential risk factors. The following precautions are recommended:

- Known severe allergy to any vaccine component, especially aluminium hydroxide - History of anaphylactic reaction to a previous hepatitis A vaccine dose - Acute moderate or severe illness at the time of vaccination - Immunocompromised conditions that may affect vaccine response - Pregnancy or breastfeeding status should be discussed with a clinician - Use caution in children with chronic liver disease or clotting disorders

Havrix Junior may interact with other agents that influence immune function or increase the risk of adverse reactions. Consider the following guidance when co‑administering other medications or vaccines.

Avoid: - Simultaneous administration with live viral vaccines without medical advice - Use of systemic corticosteroids at high doses around the time of vaccination - Concomitant receipt of other inactivated vaccines that share the same injection site

Use with caution: - Antipyretic or analgesic medications taken prophylactically before injection - Immunoglobulin therapy that could interfere with antibody development - Blood products administered within two weeks prior to vaccination